{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:55:34Z","timestamp":1791024934863,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014849","name":"Government of Valencia Department of Education Culture and University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejpb.2026.115232","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:20:37Z","timestamp":1788362437000},"page":"115232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4799-9076","authenticated-orcid":false,"given":"Javier","family":"Zarzoso-Foj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6352-8845","authenticated-orcid":false,"given":"Marina","family":"Cuquerella-Gilabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Reig-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Mangas-Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garc\u00eda-Arieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115232_b0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cpt.28","article-title":"Novel bioequivalence approach for narrow therapeutic index drugs","volume":"97","author":"Yu","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0010","unstructured":"Bioequivalence and labelling of medicines with regard to generic substitution, (n.d.). https:\/\/laegemiddelstyrelsen.dk\/en\/licensing\/licensing-of-medicines\/marketing-authorisation\/application-for-marketing-authorisation\/bioequivalence-and-labelling-of-medicines-with-regard-to-generic-substitution\/ (accessed November 19, 2025)."},{"key":"10.1016\/j.ejpb.2026.115232_b0015","unstructured":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects - Canada.ca, (n.d.). https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/comparative-bioavailability-standards-formulations-used-systemic-effects.html (accessed November 19, 2025)."},{"key":"10.1016\/j.ejpb.2026.115232_b0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","article-title":"Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update","volume":"11","author":"Bertilsson","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2026.115232_b0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0009-9236(99)70132-3","article-title":"A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine","volume":"65","author":"Yacobi","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002280050443","article-title":"Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates","volume":"54","author":"Aldenkamp","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0035","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Bioequivalence for Immediate-Release Solid Oral Dosage Forms (M13A), 2024."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115232_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/s12248-025-01158-y","article-title":"The role of early exposure metrics (pAUC0-3h and Cmax,0-3h) in assessing the bioequivalence of methylphenidate extended-release products_a sensitivity analysis","volume":"28","author":"Hsu","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115232_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106718","article-title":"The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_a sensitivity analysis","volume":"195","author":"Wang","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115232_b0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11095-012-0862-x","article-title":"Use of partial AUC (PAUC) to evaluate bioequivalence\u2014a case study with complex absorption: methylphenidate","volume":"30","author":"Fourie Zirkelbach","year":"2012","journal-title":"Pharm. Res."},{"issue":"17","key":"10.1016\/j.ejpb.2026.115232_b0055","article-title":"Partial AUCs in long-acting injectables: rationale, challenges, variability, usefulness, and clinical relevance","volume":"17","author":"Tsakiridou","year":"2024","journal-title":"Pharmaceutics 2025"},{"key":"10.1016\/j.ejpb.2026.115232_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106127","article-title":"Assessment of the impact of partial area under the curve in a bioavailability\/bioequivalence study on generic prolonged-release formulations","volume":"171","author":"Soares","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115232_b0065","doi-asserted-by":"crossref","first-page":"80-","DOI":"10.1208\/s12248-022-00726-w","article-title":"A simulation study of the comparative performance of partial area under the curve (pAUC) and partial area under the effect curve (pAUEC) metrics in crossover versus replicated crossover bioequivalence studies for concerta and Ritalin LA","volume":"24","author":"Jackson","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115232_b0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2125.2007.02984.x","article-title":"Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets","volume":"65","author":"Tothfalusi","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200140080-00001","article-title":"Measures of exposure versus measures of rate and extent of absorption","volume":"40","author":"Chen","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2026.115232_b0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2026.115232_b0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5414\/CP201845","article-title":"Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations","volume":"51","author":"Tothfalusi","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2008.10.023","article-title":"Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics","volume":"36","author":"Fern\u00e1ndez-Teruel","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115232_b0095","unstructured":"Food and Drug Administration, Draft Guidance on Carbamazepine, 2015. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/index.cfm."},{"key":"10.1016\/j.ejpb.2026.115232_b0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12372","article-title":"Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives","volume":"8","author":"Marshall","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0105","doi-asserted-by":"crossref","DOI":"10.1208\/aapsj070355","article-title":"Pharmacokinetics\/Pharmacodynamics and the stages of drug development: role of modeling and simulation","volume":"7","author":"Chien","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2026.115232_b0110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/psp4.12223","article-title":"Commentary on the MID3 good practices paper","volume":"6","author":"Manolis","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0115","unstructured":"Physiologically Based Pharmacokinetic Analyses \u2014 Format and Content Guidance for Industry | FDA, (n.d.). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry (accessed November 18, 2025)."},{"key":"10.1016\/j.ejpb.2026.115232_b0120","unstructured":"Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation - Scientific guideline | European Medicines Agency (EMA), (n.d.). https:\/\/www.ema.europa.eu\/en\/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation-scientific-guideline (accessed November 18, 2025)."},{"key":"10.1016\/j.ejpb.2026.115232_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/pharmaceutics13020270","article-title":"Pharmacokinetics of the CYP3A4 and CYP2B6 inducer carbamazepine and its drug\u2013drug interaction potential: a physiologically based pharmacokinetic modeling approach","volume":"13","author":"Fuhr","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115232_b0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/pharmaceutics16060737","article-title":"Applying physiologically based pharmacokinetic modeling to interpret carbamazepine\u2019s nonlinear pharmacokinetics and its induction potential on cytochrome P450 3A4 and cytochrome P450 2C9 enzymes","volume":"16","author":"Yin","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115232_b0135","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cpt.3151","article-title":"Assessment of the CYP3A4 induction potential by carbamazepine: insights from two clinical DDI studies and PBPK modeling","volume":"115","author":"Kanefendt","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/psp4.12134","article-title":"Applied concepts in PBPK modeling: how to build a PBPK\/PD model","volume":"5","author":"Kuepfer","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1528-1157.1990.tb05384.x","article-title":"Absolute bioavailability of carbamazepine after oral administration of a 2% syrup","volume":"31","author":"G\u00e9rardin","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0150","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00561556","article-title":"Distribution and elimination kinetics of carbamazepine in man","volume":"8","author":"Rawlins","year":"1975","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF01064556","article-title":"Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses","volume":"4","author":"G\u00e9rardin","year":"1976","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115232_b0165","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2165\/00003088-198510010-00004","article-title":"Carbamazepine metabolism in man. Induction and pharmacogenetic aspects","volume":"10","author":"Eichelbaum","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2026.115232_b0170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1248\/bpb1978.10.652","article-title":"Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans","volume":"10","author":"Sumi","year":"1987","journal-title":"J. Pharmacobiodyn."},{"key":"10.1016\/j.ejpb.2026.115232_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/clpt.1983.8","article-title":"Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide","volume":"33","author":"Tomson","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1528-1157.1978.tb04487.x","article-title":"Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine","volume":"19","author":"Wada","year":"1978","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0185","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ptr.5302","article-title":"Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers","volume":"29","author":"Bedada","year":"2015","journal-title":"Phytother. Res."},{"key":"10.1016\/j.ejpb.2026.115232_b0190","first-page":"46","article-title":"Effect of piperine on the metabolism and pharmacokinetics of carbamazepine in healthy volunteers","volume":"67","author":"Bedada","year":"2017","journal-title":"Drug Res."},{"key":"10.1016\/j.ejpb.2026.115232_b0195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00228-005-0940-7","article-title":"Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects","volume":"61","author":"Kim","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0200","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1023\/A:1015872626887","article-title":"The bioinequivalence of carbamazepine tablets with a history of clinical failures","volume":"9","author":"Meyer","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115232_b0205","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1023\/A:1011929300613","article-title":"The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets","volume":"15","author":"Meyer","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115232_b0210","first-page":"63","article-title":"Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers","volume":"24","author":"Shahzadi","year":"2011","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115232_b0215","doi-asserted-by":"crossref","unstructured":"B. Saint-Salvi, D. Tremblay, A. Surjus, M.A. Lefebvre, A study of the interaction of roxithromycin with theophylline and carbamazepine, J. Antimicrob. Chemother. 20 Suppl B (1987) 121\u2013129. doi: 10.1093\/JAC\/20.SUPPL_B.121.","DOI":"10.1093\/jac\/20.suppl_B.121"},{"key":"10.1016\/j.ejpb.2026.115232_b0220","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2125.1987.tb03257.x","article-title":"Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite","volume":"24","author":"Barzaghi","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1528-1157.1987.tb03625.x","article-title":"Pharmacokinetic interactions of progabide with other antiepileptic drugs","volume":"28","author":"Bianchetti","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-642-85921-2_15","article-title":"Pharmacokinetic data of carbamazepine and its major metabolites in man","author":"Faigle","year":"1975","journal-title":"Clinical Pharmacology of Anti-Epileptic Drugs"},{"key":"10.1016\/j.ejpb.2026.115232_b0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/mp800128y","article-title":"Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation","volume":"6","author":"Kova\u0109evi\u0107","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115232_b0240","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1528-1157.1975.tb04762.x","article-title":"Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients","volume":"16","author":"Morselli","year":"1975","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0245","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-0773.1977.tb02157.x","article-title":"The pharmacokinetics of carbamazepine in plasma and saliva of man","volume":"41","author":"Pynn\u00f6nen","year":"1977","journal-title":"Acta Pharmacol. Toxicol. (copenh)"},{"key":"10.1016\/j.ejpb.2026.115232_b0250","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/clpt.1983.62","article-title":"Effect of erythromycin on carbamazepine kinetics","volume":"33","author":"Wong","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0255","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cpt1975176657","article-title":"Pharmacokinetics of carbamazepine in normal man","volume":"17","author":"Levy","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1528-1157.1985.tb05395.x","article-title":"The influence of cimetidine on single-dose carbamazepine pharmacokinetics","volume":"26","author":"Dalton","year":"1985","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0265","first-page":"941","article-title":"Ranitidine does not alter single-dose carbamazepine pharmacokinetics in healthy adults","volume":"19","author":"Dalton","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.ejpb.2026.115232_b0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00561065","article-title":"The pharmacokinetics of carbamazepine","volume":"12","author":"Cotter","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0275","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/0091270008319792","article-title":"Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects","volume":"48","author":"Ji","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00007691-198901000-00010","article-title":"Erythromycin effects on multiple-dose carbamazepine kinetics","volume":"11","author":"Miles","year":"1989","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2026.115232_b0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00191168","article-title":"Early stage autoinduction of carbamazepine metabolism in humans","volume":"47","author":"Bernus","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0290","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpb.2026.115232_b0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2026.115232_b0300","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1067\/mcp.2000.111530","article-title":"Lack of effect of St John\u2019s Wort on carbamazepine pharmacokinetics in healthy volunteers","volume":"68","author":"Burstein","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0305","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00004714-200110000-00007","article-title":"Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects","volume":"21","author":"M\u00f8ller","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0310","unstructured":"Tegretol 100mg Tablets - Summary of Product Characteristics (SmPC) - (emc) | 1040, (n.d.). https:\/\/www.medicines.org.uk\/emc\/product\/1040\/smpc#gref (accessed January 20, 2026)."},{"key":"10.1016\/j.ejpb.2026.115232_b0315","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0320","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70295","article-title":"Best practices in physiologically based pharmacokinetic (PBPK) modeling","volume":"15","author":"Chenel","year":"2026","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115232_b0325","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.xphs.2021.02.019","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: carbamazepine","volume":"110","author":"Garc\u00eda","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115232_b0330","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), ICH M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms, (2024). https:\/\/www.ich.org\/page\/multidisciplinary-guidelines#13-0 (accessed February 21, 2026)."},{"key":"10.1016\/j.ejpb.2026.115232_b0335","unstructured":"FDA, Tegretol, (n.d.). https:\/\/www.accessdata.fda.gov\/spl\/data\/389c8283-786d-4ab3-af81-507a86aae802\/389c8283-786d-4ab3-af81-507a86aae802.xml (accessed January 20, 2026)."},{"key":"10.1016\/j.ejpb.2026.115232_b0340","unstructured":"E.M.A. (EMA) Committee for Medicinal Products for Human Use (CHMP), Guideline on the Investigation of Bioequivalence, 1997. http:\/\/www.ema.europa.eu."},{"key":"10.1016\/j.ejpb.2026.115232_b0345","unstructured":"F. and D.A. U.S. Department of Health and Human Services, Statistical Approaches to Establishing Bioequivalence - Guidance for Industry - Biopharmaceutics, Generic Drugs, 2026. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs."},{"key":"10.1016\/j.ejpb.2026.115232_b0350","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/cpt.2174","article-title":"Use of partial area under the curve in bioavailability or bioequivalence assessments: a regulatory perspective","volume":"110","author":"Fang","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115232_b0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0928-0987(97)00073-0","article-title":"Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration","volume":"6","author":"Duquesnoy","year":"1998","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115232_b0360","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cpt.3561","article-title":"A 2024 Update on US FDA implementation of partial area under the curve into bioavailability and bioequivalence assessments","volume":"117","author":"Hopefl","year":"2025","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:47:43Z","timestamp":1791024463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":72,"alternative-id":["S0939641126002535"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115232","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115232"}}